Is Bone Biologics Stock a Good Investment?
Bone Biologics Investment Advice | BBLGW |
- Examine Bone Biologics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bone Biologics' leadership team and their track record. Good management can help Bone Biologics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Bone Biologics' business and its evolving consumer preferences.
- Compare Bone Biologics' performance and market position to its competitors. Analyze how Bone Biologics is positioned in terms of product offerings, innovation, and market share.
- Check if Bone Biologics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bone Biologics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bone Biologics Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bone Biologics Corp is a good investment.
Sell | Buy |
Buy
Market Performance | Insignificant | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Bone Biologics Stock
Researching Bone Biologics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.14. Bone Biologics Corp had not issued any dividends in recent years. The entity had 1:30 split on the 7th of June 2023.
To determine if Bone Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bone Biologics' research are outlined below:
| Bone Biologics Corp is way too risky over 90 days horizon | |
| Bone Biologics Corp appears to be risky and price may revert if volatility continues | |
| Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp has accumulated about 4.44 K in cash with (9.56 M) of positive cash flow from operations. | |
| Bone Biologics Corp has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Hankey Bret of 1063830 shares of Bone Biologics subject to Rule 16b-3 |
Bone Biologics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.39) | (2.51) | |
| Return On Capital Employed | (3.24) | (3.08) | |
| Return On Assets | (2.39) | (2.51) | |
| Return On Equity | (3.08) | (2.93) |
Determining Bone Biologics' profitability involves analyzing its financial statements and using various financial metrics to determine if Bone Biologics is a good buy. For example, gross profit margin measures Bone Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bone Biologics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bone Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bone Biologics Corp. Check Bone Biologics' Beneish M Score to see the likelihood of Bone Biologics' management manipulating its earnings.
Evaluate Bone Biologics' management efficiency
The company has return on total asset (ROA) of (0.5725) % which means that it has lost $0.5725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1903) %, meaning that it generated substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.51 in 2024. Return On Capital Employed is likely to climb to -3.08 in 2024. At this time, Bone Biologics' Other Current Assets are fairly stable compared to the past year. Other Assets is likely to climb to 1,155 in 2024, whereas Total Current Assets are likely to drop slightly above 2.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.05 | 11.60 | |
| Net Current Asset Value | -4.2 K | -4.4 K | |
| Tangible Asset Value | -4.2 K | -4.4 K | |
| Tangible Book Value Per Share | 11.05 | 11.60 | |
| Enterprise Value Over EBITDA | (3.45) | (3.62) | |
| Price Book Value Ratio | 0.41 | 0.43 | |
| Enterprise Value Multiple | (3.45) | (3.62) | |
| Price Fair Value | 0.41 | 0.43 | |
| Enterprise Value | -2.1 M | -2 M |
At Bone Biologics Corp, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.736 |
Basic technical analysis of Bone Stock
As of the 22nd of November, Bone Biologics shows the Mean Deviation of 5.38, standard deviation of 23.72, and Risk Adjusted Performance of 0.0519. Bone Biologics Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Bone Biologics Corp variance and kurtosis to decide if Bone Biologics Corp is priced correctly, providing market reflects its regular price of 28.49 per share. Given that Bone Biologics has variance of 562.77, we suggest you to validate Bone Biologics Corp's prevailing market performance to make sure the company can sustain itself at a future point.Bone Biologics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bone Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hankey Bret over two weeks ago Acquisition by Hankey Bret of 1063830 shares of Bone Biologics subject to Rule 16b-3 | ||
Heshmatpour Amir F over three months ago Acquisition by Heshmatpour Amir F of 200000 shares of Bone Biologics subject to Rule 16b-3 | ||
Hankey Don over six months ago Acquisition by Hankey Don of 553191 shares of Bone Biologics subject to Rule 16b-3 | ||
Delshad Jim over six months ago Acquisition by Delshad Jim of 26780 shares of Bone Biologics at 2.05 subject to Rule 16b-3 | ||
Deina Walsh over six months ago Acquisition by Deina Walsh of 12500 shares of Bone Biologics at 3.61 subject to Rule 16b-3 |
Understand Bone Biologics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bone Biologics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0519 | |||
| Market Risk Adjusted Performance | 1.1 | |||
| Mean Deviation | 5.38 | |||
| Coefficient Of Variation | 1808.05 | |||
| Standard Deviation | 23.72 | |||
| Variance | 562.77 | |||
| Information Ratio | 0.0507 | |||
| Jensen Alpha | 1.18 | |||
| Total Risk Alpha | (1.79) | |||
| Treynor Ratio | 1.09 | |||
| Maximum Drawdown | 183.08 | |||
| Skewness | 5.3 | |||
| Kurtosis | 45.4 |
| Risk Adjusted Performance | 0.0519 | |||
| Market Risk Adjusted Performance | 1.1 | |||
| Mean Deviation | 5.38 | |||
| Coefficient Of Variation | 1808.05 | |||
| Standard Deviation | 23.72 | |||
| Variance | 562.77 | |||
| Information Ratio | 0.0507 | |||
| Jensen Alpha | 1.18 | |||
| Total Risk Alpha | (1.79) | |||
| Treynor Ratio | 1.09 | |||
| Maximum Drawdown | 183.08 | |||
| Skewness | 5.3 | |||
| Kurtosis | 45.4 |
Consider Bone Biologics' intraday indicators
Bone Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bone Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.9 | |||
| Day Median Price | 28.49 | |||
| Day Typical Price | 28.49 | |||
| Price Action Indicator | (1.65) | |||
| Period Momentum Indicator | (3.29) |
Bone Biologics Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 21st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 18th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Bone Stock media impact
Far too much social signal, news, headlines, and media speculation about Bone Biologics that are available to investors today. That information is available publicly through Bone media outlets and privately through word of mouth or via Bone internal channels. However, regardless of the origin, that massive amount of Bone data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bone Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bone Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bone Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bone Biologics alpha.
Bone Biologics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bone Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bone Biologics Corporate Executives
Elected by the shareholders, the Bone Biologics' board of directors comprises two types of representatives: Bone Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bone. The board's role is to monitor Bone Biologics' management team and ensure that shareholders' interests are well served. Bone Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bone Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shunichi Kuroda | CoFounder Board | Profile |
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.